Get the Stockscreener App
2.33
1.30%
0.03
After Hours:
2.33
Nkarta Inc stock is traded at $2.33, with a volume of 302.40K.
It is up +1.30% in the last 24 hours and down -12.08% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.30
Open:
$2.31
24h Volume:
302.40K
Relative Volume:
0.46
Market Cap:
$166.89M
Revenue:
-
Net Income/Loss:
$-104.08M
P/E Ratio:
-1.6561
EPS:
-1.4069
Net Cash Flow:
$-89.91M
1W Performance:
-3.32%
1M Performance:
-12.08%
6M Performance:
+18.27%
1Y Performance:
+5.91%
1-Day Range:
$2.2406
$2.34
1-Week Range:
$2.2406
$2.48
52-Week Range:
$1.70
$3.72
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.33 | 171.18M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen - marketbeat.com
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Canada
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - marketbeat.com
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - kalkine.ca
Equities Analysts Set Expectations for Nkarta Q3 Earnings - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (KkQAHM32gq) - Mshale
Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside - TradingView
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
NKARTA, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16 - Bitget
Nkarta, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS - marketbeat.com
Nkarta Q2 EPS of $(0.54) misses $(0.38) analyst estimate - scanx.trade
Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029 - Quiver Quantitative
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Nkarta, Inc. expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Nkarta Inc. (NKTX) Drops 2.79% to $2.09 as Key Support Level Comes into FocusLate Stage Breakouts - dars.gov.et
Nkarta (NASDAQ:NKTX) Upgraded at Wall Street Zen - MarketBeat
Nkarta Stock Price Forecast. Should You Buy NKTX? - StockInvest.us
Nkarta, Inc. Revenue Breakdown – NASDAQ:NKTX - TradingView
NKTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NKTX|Nkarta Inc|Price:2.245|Chg%:-0.025 - TradingKey
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nkarta Inc. (NKTX) Edges Higher: Biotech Stock Tests Key Levels After 3.5% GainEarly Entry Signals - dars.gov.et
Nkarta Market Sentiment - Benzinga España
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nkarta Inc (NKTX) Balance Sheet - TradingKey
Nkarta Inc (NKTX) Cash Flow - TradingKey
Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nkarta Inc. (NKTX) Holds Steady at $2.6 as Consolidation ContinuesPassive Flow - dars.gov.et
Nkarta Inc. (NKTX) Declines 4.9% as Biotech Headwinds Persist — Key Support in FocusTICK Divergence - dars.gov.et
Nkarta Inc. (NKTX) Slides 5% as Biotech Momentum Fades, Tests Near-Term SupportHigh Reward Trades - dars.gov.et
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit Stock GainProfit Growth Outlook - dars.gov.et
Nkarta (NKTX) Stock Analysis Report | Financials & Insights - Benzinga España
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss in Early-Stage BiotechEarnings Revision Downgrade - dars.gov.et
Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to book forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Enterprise value to revenue forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to earnings forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):